Concord Asset Management LLC VA Buys 2,605 Shares of Aflac Incorporated (NYSE:AFL)

Concord Asset Management LLC VA lifted its holdings in shares of Aflac Incorporated (NYSE:AFL - Free Report) by 34.3% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,189 shares of the financial services provider's stock after acquiring an additional 2,605 shares during the quarter. Concord Asset Management LLC VA's holdings in Aflac were worth $1,105,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in AFL. Vanguard Group Inc. grew its holdings in Aflac by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 51,340,298 shares of the financial services provider's stock worth $5,310,640,000 after acquiring an additional 653,275 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Aflac by 2.4% during the 4th quarter. Geode Capital Management LLC now owns 12,465,433 shares of the financial services provider's stock valued at $1,286,042,000 after buying an additional 288,482 shares during the last quarter. Northern Trust Corp grew its position in shares of Aflac by 22.9% during the 4th quarter. Northern Trust Corp now owns 7,296,014 shares of the financial services provider's stock valued at $754,700,000 after buying an additional 1,357,753 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Aflac by 11.9% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,250,905 shares of the financial services provider's stock valued at $543,154,000 after buying an additional 556,394 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Aflac during the 4th quarter valued at about $349,699,000. Institutional investors and hedge funds own 67.44% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Barclays set a $98.00 price objective on shares of Aflac and gave the stock an "underweight" rating in a report on Monday, July 7th. Raymond James Financial decreased their target price on shares of Aflac from $115.00 to $110.00 and set an "outperform" rating for the company in a research report on Thursday, May 29th. Piper Sandler increased their target price on shares of Aflac from $118.00 to $124.00 and gave the company an "overweight" rating in a research report on Wednesday, April 2nd. Keefe, Bruyette & Woods increased their target price on shares of Aflac from $104.00 to $106.00 and gave the company a "market perform" rating in a research report on Wednesday, May 7th. Finally, Wells Fargo & Company set a $105.00 target price on shares of Aflac and gave the company an "equal weight" rating in a research report on Thursday, July 10th. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $107.07.

Aflac Price Performance

NYSE AFL traded up $0.36 during trading hours on Friday, reaching $101.78. 4,568,711 shares of the company's stock were exchanged, compared to its average volume of 2,163,157. The stock has a market cap of $55.03 billion, a PE ratio of 15.90, a price-to-earnings-growth ratio of 3.14 and a beta of 0.81. Aflac Incorporated has a one year low of $92.44 and a one year high of $115.50. The firm has a fifty day moving average of $103.41 and a 200-day moving average of $105.18. The company has a current ratio of 0.09, a quick ratio of 0.09 and a debt-to-equity ratio of 0.29.

Aflac (NYSE:AFL - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The financial services provider reported $1.66 EPS for the quarter, missing analysts' consensus estimates of $1.67 by ($0.01). Aflac had a return on equity of 15.55% and a net margin of 21.27%. The business had revenue of $3.40 billion for the quarter, compared to the consensus estimate of $4.53 billion. During the same quarter last year, the company earned $1.66 earnings per share. The firm's revenue was down 37.5% on a year-over-year basis. On average, equities research analysts predict that Aflac Incorporated will post 6.88 earnings per share for the current fiscal year.

Aflac Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Stockholders of record on Wednesday, May 21st were issued a $0.58 dividend. This represents a $2.32 annualized dividend and a dividend yield of 2.28%. The ex-dividend date was Wednesday, May 21st. Aflac's dividend payout ratio (DPR) is 36.25%.

Insider Activity

In other Aflac news, Director Masatoshi Koide sold 37,000 shares of Aflac stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $105.59, for a total value of $3,906,830.00. Following the sale, the director directly owned 70,992 shares in the company, valued at approximately $7,496,045.28. The trade was a 34.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Arthur Reginald Collins sold 2,750 shares of the firm's stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $105.70, for a total transaction of $290,675.00. Following the sale, the director owned 6,728 shares of the company's stock, valued at approximately $711,149.60. This represents a 29.01% decrease in their position. The disclosure for this sale can be found here. Insiders sold 40,750 shares of company stock valued at $4,304,295 in the last quarter. Company insiders own 0.90% of the company's stock.

About Aflac

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.